Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with HIV: A Real-World Data from the Spanish BICSTaR Cohort
These real-world findings strongly support B/F/TAF use in TN and TE people with HIV in Spain, demonstrating high 12-month persistence and effectiveness, and mental health benefits in TN participants, with minimal adverse events.
Authors
- Cristina de Álvaro
- Celia Miralles
- Ana González-Cordón (ORCID: https://orcid.org/0000-0002-0894-3711)
- Miguel García Deltoro (ORCID: https://orcid.org/0000-0002-5969-1059)
- Boris Revollo (ORCID: https://orcid.org/0000-0001-9245-2183)
- Joaquín Portilla (ORCID: https://orcid.org/0000-0002-3676-9511)
- Johanna Ramroth
- Josep Mallolas (ORCID: https://orcid.org/0000-0002-8365-141X)
- Alexy Inciarte (ORCID: https://orcid.org/0000-0003-1896-3457)
- Antonio Antela (ORCID: https://orcid.org/0000-0002-4819-0953)
- Ana Silva‐Klug (ORCID: https://orcid.org/0000-0003-4660-534X)
- Manuel Ángel Castaño Carracedo
Institutions
- Bellvitge University Hospital (ES)
- University Hospital Complex Of Vigo (ES)
- Complejo Hospitalario Universitario de Santiago (ES)
- Hospital Regional Universitario de Málaga (ES)
- Hospital Clínic de Barcelona (ES)
- Instituto Bernabeu (ES)
- Gilead Sciences (Spain) (ES)
- Hospital General Universitario De Valencia (ES)
- Hospital General Universitario de Alicante Doctor Balmis (ES)
- Hospital Universitari Germans Trias i Pujol (ES)
- Diagnostics for the Real World (United Kingdom) (GB)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- HIV/AIDS - Research and Palliative Care
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2147/hiv.s528859
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Daiichi-Sankyo